Trial NCT04421027
Publication COV-BARRIER - Ely EW, Lancet Respir Med (2022) (published paper)
Primary outcome on the report: All-cause mortality by day 28 and day 60; number of ventilator-free days; overall improvement (assessed by odds of improvement in clinical status) on National Institute of Allergy and Infectious Disease Ordinal Scale (NIAID-OS) evaluated at days 4, 7, 10, 14, and 28; proportion of participants with at least 1-point improvement on the NIAID-OS or live discharge from the hospital at days 4, 7, 10, 14, and 28; duration of hospitalisation; and time to recovery through day 28.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.